Oncoinvent ASA (LON:0RU5)

Market Cap	14.83M
Revenue (ttm)	1.44M +247.1%
Net Income	-7.70M
EPS	-6.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,700
Average Volume	178
Open	43.29
Previous Close	42.56
Day's Range	42.50 - 43.29
52-Week Range	41.28 - 132.00
Beta	n/a
RSI	30.19
Earnings Date	Feb 26, 2026

About Oncoinvent ASA

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 36
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RU5

Financial Performance

In 2024, Oncoinvent ASA's revenue was 8.10 million, an increase of 39.95% compared to the previous year's 5.79 million. Losses were -140.20 million, -2.38% less than in 2023.

Financial numbers in NOK